Ocular Therapeutix, Inc. is a U.S.-based biopharmaceutical company focused on ophthalmology, with products and product candidates built around its ELUTYX bioresorbable hydrogel delivery technology. Its portfolio includes the approved ocular therapy DEXTENZA and investigational programs for retinal disease and glaucoma, including AXPAXLI and OTX-TIC.
−511,4 %
87,3 %
−511,9 %
−18,5 %
15.39
15.32
| % | |
|---|---|
| Commercial ophthalmic product | 100% DEXTENZA is the company’s approved ocular insert sold in the U.S. for post-surgical inflammation, pain, and allergic conjunctivitis. |
| Retinal disease pipeline | 0% AXPAXLI is an investigational intravitreal hydrogel candidate being developed for wet AMD and diabetic retinal disease. |
| Glaucoma pipeline | 0% OTX-TIC is an investigational intracameral hydrogel candidate for open-angle glaucoma and ocular hypertension. |
| Drug-delivery platform | 0% ELUTYX is the proprietary bioresorbable hydrogel platform used to deliver therapeutic agents to the eye. |
The company sells DEXTENZA primarily through a small number of specialty distributors in the United States, which then...
Buy DEXTENZA in bulk and distribute it to ophthalmic care sites; they are the main commercial channel.
Use DEXTENZA in connection with ophthalmic surgery, especially cataract-related procedures.
Purchase DEXTENZA for outpatient eye-surgery workflows and post-operative care.
Use office-administered DEXTENZA for approved indications and may adopt future office-based therapies.
Potential future prescribers of AXPAXLI and OTX-TIC if those candidates are approved.
Ocular Therapeutix is headquartered in the United States and derives its commercial product revenue from U.S...
The company’s strategy centers on building an ophthalmology franchise around its ELUTYX hydrogel platform, using...
AXPAXLI is the main pipeline asset and could expand the company beyond DEXTENZA.
Commercial execution on the approved product supports the base business and physician familiarity with the platform.
A common delivery platform can create a pipeline of differentiated products with local release properties.
Licensing can extend reach without building a full international commercial infrastructure.
The business depends on a narrow commercial base, a small number of specialty distributors, and successful adoption by...
A small number of specialty distributors account for most revenue, so losing one could materially reduce sales.
AXPAXLI and OTX-TIC are still investigational, and trial setbacks would delay or eliminate future product revenue.
Ophthalmic drugs require FDA and other regulatory approvals before commercialization.
If patent protection is narrower than expected, competitors could launch similar products.
Alternative therapies may be cheaper, more convenient, or better reimbursed, limiting adoption.
EYPT · Laboratory Analytical Instruments
OTLK · Biological Products, (No Diagnostic Substances)
IRIX · Electromedical & Electrotherapeutic Apparatus
IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases.
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
GKOS · Surgical & Medical Instruments & Apparatus
Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments.
: 29/04/2026